India Inc Calls For Regulatory Easing; Looks To Biosimilar Launches Including Keytruda

 
• By Vibha Ravi

Speaking of an impending launch of new biosimilars, including pembrolizumab, panelists at a recent event in India asked for regulatory easing from a waiver of Phase III trials for biosimilars to a single body for pre-clinical and trial approvals. The chicken and egg question of VC funding also came up.

IPA 2024 Summit Patient Needs Panel
Left To Right - Ratnesh Jain, MD, Mumbai Biocluster; Ravi Shankara, Sr GM, Sun Pharma; Dhananjay Patankar, former VP, Syngene; Sanjeev Gupta, Sr VP Ipca Labs • Source: Scrip/Citeline

More from Business

More from Scrip